Facultad de Medicina (FM)
Centro académico
VU University Amsterdam
Ámsterdam, HolandaPublications en collaboration avec des chercheurs de VU University Amsterdam (38)
2024
-
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function
European Journal of Heart Failure, Vol. 26, Núm. 4, pp. 707-729
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators
Journal of Prevention of Alzheimer's Disease
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2023
-
Advanced MR Techniques for Preoperative Glioma Characterization: Part 1
Journal of Magnetic Resonance Imaging, Vol. 57, Núm. 6, pp. 1655-1675
-
Advanced MR Techniques for Preoperative Glioma Characterization: Part 2
Journal of Magnetic Resonance Imaging, Vol. 57, Núm. 6, pp. 1676-1695
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Blood, Vol. 141, Núm. 3, pp. 219-230
-
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
2022
-
Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: A joint EORTC BTG and RANO effort
Neuro-oncology, Vol. 24, Núm. 10, pp. 1726-1735
-
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study
Cancers, Vol. 14, Núm. 3
2021
-
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003
-
Endocrine and Growth Abnormalities in 4H Leukodystrophy Caused by Variants in POLR3A, POLR3B, and POLR1C
Journal of Clinical Endocrinology and Metabolism, Vol. 106, Núm. 2, pp. E660-E674
-
Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes
Biological Psychiatry, Vol. 89, Núm. 8, pp. 825-835
-
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
Journal of Hematology and Oncology
2020
-
Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)
Acta Neuropathologica
-
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 8, pp. 1885-1912